This company listing is no longer active
ACGN Stock Overview
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Aceragen, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.38 |
52 Week High | US$16.00 |
52 Week Low | US$0.36 |
Beta | 1.14 |
11 Month Change | -48.99% |
3 Month Change | -76.54% |
1 Year Change | -95.55% |
33 Year Change | -98.96% |
5 Year Change | -99.78% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Shareholder Returns
ACGN | US Biotechs | US Market | |
---|---|---|---|
7D | -11.6% | 6.1% | 4.2% |
1Y | -95.5% | 20.1% | 24.4% |
Return vs Industry: ACGN underperformed the US Biotechs industry which returned 6.3% over the past year.
Return vs Market: ACGN underperformed the US Market which returned 4.2% over the past year.
Price Volatility
ACGN volatility | |
---|---|
ACGN Average Weekly Movement | 23.7% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.4% |
10% most volatile stocks in US Market | 15.2% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACGN's share price has been volatile over the past 3 months.
Volatility Over Time: ACGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 26 | John Taylor | www.aceragen.com |
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia.
Aceragen, Inc. Fundamentals Summary
ACGN fundamental statistics | |
---|---|
Market cap | US$3.20m |
Earnings (TTM) | -US$41.05m |
Revenue (TTM) | US$7.33m |
0.4x
P/S Ratio-0.1x
P/E RatioIs ACGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACGN income statement (TTM) | |
---|---|
Revenue | US$7.33m |
Cost of Revenue | US$15.40m |
Gross Profit | -US$8.06m |
Other Expenses | US$32.98m |
Earnings | -US$41.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.88 |
Gross Margin | -110.00% |
Net Profit Margin | -559.86% |
Debt/Equity Ratio | 1.3% |
How did ACGN perform over the long term?
See historical performance and comparison